Michael Tuscan

Cooley advised EyeBiotech Limited, a privately held, clinical-stage ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases, on the close of an extension to its Series A financing, bringing the total raised to date to $130 million.

Cooley advised MapLight Therapeutics, a clinical-stage biopharmaceutical company, on its oversubscribed $225 million Series C financing.

Cooley advised global investment firm Sixth Street on its strategic investment in Blueprint Medicines, a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Lawyers Mischi a Marca, Matt Browne, Matt Scarano, Addison Pierce, Matt Kong and Nick Neuteufel led the Cooley team advising Sixth Street. 

Cooley advised Forbius – a clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases – on its agreement to sell to Bristol Myers Squibb. Barbara Borden, Marya Postner and Rowook Park led the Cooley team advising Forbius. 

Cooley advised Iconic Therapeutics on the closing of its $40 million Series C financing. The round included new investors HBM Healthcare Investments, Cormorant Asset Management and Osage University Partners. All of Iconic's existing investors, including MPM Capital, H.I.G. Capital and Lundbeck fund Ventures, participated in the round.

According to Iconic, proceeds from the financing will be used to advance development of lead molecule ICON-1 in retinal diseases as well as begin clinical trials in ocular melanoma, Iconic's first oncology indication.

Iconic is a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer.

The team advising Iconic included Mark Weeks, Anita Vasudevan, Daniel Elefant, Mike Tuscan and Marya Postner.